- Home
- PNI vs IFRX Comparison
PNI vs IFRX Comparison
Compare PNI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- IFRX
- Stock Information
- Founded
- PNI 2002
- IFRX 2007
- Country
- PNI United States
- IFRX Germany
- Employees
- PNI N/A
- IFRX N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- PNI Finance
- IFRX Health Care
- Exchange
- PNI Nasdaq
- IFRX Nasdaq
- Market Cap
- PNI 75.3M
- IFRX 65.8M
- IPO Year
- PNI N/A
- IFRX 2017
- Fundamental
- Price
- PNI $6.66
- IFRX $0.84
- Analyst Decision
- PNI
- IFRX Strong Buy
- Analyst Count
- PNI 0
- IFRX 4
- Target Price
- PNI N/A
- IFRX $7.75
- AVG Volume (30 Days)
- PNI 26.4K
- IFRX 753.4K
- Earning Date
- PNI 01-01-0001
- IFRX 05-07-2025
- Dividend Yield
- PNI 4.76%
- IFRX N/A
- EPS Growth
- PNI N/A
- IFRX N/A
- EPS
- PNI N/A
- IFRX N/A
- Revenue
- PNI N/A
- IFRX $140,242.00
- Revenue This Year
- PNI N/A
- IFRX $3.36
- Revenue Next Year
- PNI N/A
- IFRX $100.60
- P/E Ratio
- PNI N/A
- IFRX N/A
- Revenue Growth
- PNI N/A
- IFRX 30.90
- 52 Week Low
- PNI $6.03
- IFRX $0.71
- 52 Week High
- PNI $7.89
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- PNI 43.59
- IFRX 32.37
- Support Level
- PNI $6.65
- IFRX $0.78
- Resistance Level
- PNI $6.75
- IFRX $0.89
- Average True Range (ATR)
- PNI 0.06
- IFRX 0.12
- MACD
- PNI -0.00
- IFRX -0.13
- Stochastic Oscillator
- PNI 23.81
- IFRX 7.78
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.